Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiora Pharmaceuticals

3.19
+0.00330.10%
Volume:8.11K
Turnover:25.84K
Market Cap:9.58M
PE:-1.11
High:3.30
Open:3.30
Low:3.15
Close:3.19
Loading ...

Kiora Pharmaceuticals: Strong Financial Position and Strategic Partnerships Propel Buy Rating

TIPRANKS
·
11 May

Kiora Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a share - Earnings Preview

Reuters
·
06 May

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy

Newsfile
·
05 May

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Newsfile
·
04 Apr

Kiora Pharmaceuticals Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Kiora Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Mar

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Newsfile
·
25 Mar

Kiora Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

Reuters
·
21 Mar

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Newsfile
·
13 Feb

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Newsfile
·
11 Feb

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative

Simply Wall St.
·
15 Nov 2024

Kiora Pharmaceuticals: Strategic Advancements and Financial Stability Justify Buy Rating

TIPRANKS
·
13 Nov 2024

Kiora Pharmaceuticals Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024